904 Repurposing CD26 (DPP4) inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma

904 Repurposing CD26 (DPP4) inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma

Bibliographic Details
Main Authors:	Thomas Mace, Gregory Lesinski, Chrystal Paulos, Megan Wyatt, Cameron Herting, Michael Ware, Juan Sarmiento, Shishir Maithel, Bassel El-rayes, Maggie Phillips
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

823 Repurposing CD26/DPP4 inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma
by: Thomas Mace, et al.
Published: (2023-11-01)

267 Adapting orthotopic murine models of pancreatic cancer to enhance adoptive T cell immunotherapy
by: Gregory B Lesinski, et al.
Published: (2023-11-01)

403 Correlative analysis of blood and biopsy samples from a clinical trial of Hsp90 inhibition in combination with pembrolizumab reveals increased intratumoral myeloid cell accumulation after treatment
by: Mohammad Zaidi, et al.
Published: (2021-11-01)

330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies
by: Mohammad Zaidi, et al.
Published: (2020-11-01)

Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
by: Gregory B Lesinski, et al.
Published: (2020-07-01)

18 Systemic immune profiling of advanced biliary tract cancer patients defines altered cytokines and immune cell populations
by: Yuan Liu, et al.
Published: (2021-11-01)

Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
by: Rita Rebelo, et al.
Published: (2021-03-01)

CD26/DPP-4 in Chronic Myeloid Leukemia
by: Anna Sicuranza, et al.
Published: (2022-02-01)

18.904 Seminar in Topology, Fall 2005
by: Behrens, Mark
Published: (2005)

Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
by: Michael Brandon Ware, et al.
Published: (2023-04-01)

Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
by: Lui Ng, et al.
Published: (2021-07-01)

15.904 Strategic Management II, Fall 2003
by: Hax, Arnoldo C.
Published: (2003)

904 Lupus Sex Bias and TLR7 Signaling
by: Biji T Kurien, et al.
Published: (2022-12-01)

9.04 Neural Basis of Vision and Audtion, Fall 2004
by: Schiller, Peter H., et al.
Published: (2004)

9.04 Neural Basis of Vision and Audition, Fall 2006
by: Brown, M. Christian, et al.
Published: (2006)

9.04 Neural Basis of Vision and Audition, Fall 2002
by: Schiller, Peter H., et al.
Published: (2002)

1507 The Galectin-9-Tim-3 pathway is a novel checkpoint target for patients with biliary tract cancer
by: Yuan Liu, et al.
Published: (2023-11-01)

Functional roles of CD26/DPP4 in bleomycin‐induced pulmonary fibrosis
by: Yu Koyanagi, et al.
Published: (2023-03-01)

The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells
by: Guranda Chitadze, et al.
Published: (2021-11-01)

Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study
by: Veera C. S. R. Chittepu, et al.
Published: (2019-05-01)

513 CD26 enzymatic activity modulates efficient migration of adoptively transferred T cells to solid tumors
by: Chrystal Paulos, et al.
Published: (2020-11-01)

Precipitation of σ phase in superaustenitic stainless steel UHB 904L
by: F. Tehovnik, et al.
Published: (2017-01-01)

Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26?
by: M. Maia Pinheiro, et al.
Published: (2020-04-01)

Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
by: Ningna Weng, et al.
Published: (2022-07-01)

MAGNETOACOUSTIC AND BARKHAUSEN EMISSION FROM DOMAIN-WALL INTERACTIONS WITH PRECIPITATES IN INCOLOY-904
by: Buttle, D, et al.
Published: (1987)

Cysteine 904 is required for maximal insulin degrading enzyme activity and polyanion activation.
by: Eun Suk Song, et al.
Published: (2012-01-01)

Dally is not essential for Dpp spreading or internalization but for Dpp stability by antagonizing Tkv-mediated Dpp internalization
by: Niklas Simon, et al.
Published: (2024-01-01)

119 IL-6 is critical for memory responses elicited by Th17 cells to tumors
by: Gregory Lesinski, et al.
Published: (2020-11-01)

748 Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade
by: Yuan Liu, et al.
Published: (2021-11-01)

CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma
by: Sohji Nishina, et al.
Published: (2022-01-01)

398 Utilizing a Th17 polarization strategy for generating high quality human TIL products for patients with advanced solid tumors
by: Gregory B Lesinski, et al.
Published: (2023-11-01)

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
by: Emi Kawakita, et al.
Published: (2021-05-01)

Functional Roles for CD26/DPP4 in Mediating Inflammatory Responses of Pulmonary Vascular Endothelial Cells
by: Yukiko Takahashi, et al.
Published: (2021-12-01)

US patent no. 7,904,256 B2: Startup techniques for a digital flowmeter
by: Henry, M, et al.
Published: (2011)

Application of machine learning models to investigate the performance of stainless steel type 904 with agricultural waste
by: Omotayo Sanni, et al.
Published: (2022-09-01)

Obowiązek sprawowania mszy świętej oraz jej częstotliwość (kan. 904-905 KPK/1983)
by: Jarosław Kodzia
Published: (2013-01-01)

Microstructure and corrosion properties of the AISI 904L weld cladding obtained by the electro slag process
by: João V.S. Matias, et al.
Published: (2021-11-01)

223 Potent inhibition of PI3Kδ promotes enhanced T cell stemness and mitochondrial fitness
by: Chrystal Paulos, et al.
Published: (2021-11-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
by: Sruthi Ravindranathan, et al.
Published: (2022-10-01)